10-K: Haemonetics Reports Fiscal Year 2024 Results, Focuses on Growth and Efficiency

Haemonetics' fiscal year 2024 shows revenue growth driven by Plasma and Hospital segments, alongside strategic initiatives to manage costs and expand in key markets.

Summary

• Haemonetics Corporation reported a 12.0% increase in net revenues for fiscal year 2024, reaching $1,309.1 million, compared to $1,168.7 million in fiscal year 2023.
• The Plasma and Hospital segments were key drivers of this growth, while the Blood Center segment faced challenges.
• Operating income increased by 5.7% to $164.9 million, influenced by revenue growth and cost savings initiatives.
• The company is managing its business with a focus on growth in Plasma and Hospital, and cost reduction in Blood Center.
• Haemonetics completed the acquisition of OpSens Inc. in December 2023 for approximately $254.5 million, expanding its Hospital business unit.
• The company is also undertaking portfolio rationalization initiatives, incurring $13.9 million in charges during fiscal 2024.
• Haemonetics is committed to innovation, receiving FDA clearance for advancements to NexSys PCS and a new TEG 6s assay cartridge.
• The company is managing a complex global supply chain and addressing potential disruptions and cost increases.
• Haemonetics is subject to extensive government regulations and faces risks related to non-compliance.
• The company is focused on attracting and retaining key personnel and fostering a diverse and inclusive culture.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive revenue growth and strategic acquisitions, but also acknowledges risks and challenges in certain segments and regulatory compliance.

Positives

• Strong revenue growth in Plasma and Hospital segments.
• Strategic acquisition of OpSens Inc. expands the Hospital business unit.
• FDA clearances for new product advancements demonstrate innovation.
• Operational Excellence Program contributes to cost savings.
• Commitment to employee development, diversity, and inclusion.

Negatives

• Blood Center revenue decreased by 1.4%.
• The company faces intense competition across its product lines.
• The company is subject to product quality and safety concerns, leading to potential recalls.
• The company is increasingly dependent on information technology systems and subject to cyber-attack risks.
• The company has a significant amount of debt that may decrease business flexibility.

Risks

• Material reductions in purchasing from or loss of a significant customer could adversely affect the business.
• The company faces intense competition and may not be able to keep pace with rapid technological changes.
• Defects or quality issues associated with products could adversely affect the results of operations.
• The company is increasingly dependent on information technology systems and subject to cyber-attack risks.
• An interruption in the ability to manufacture products or obtain key components may adversely affect the business.
• Changes in the cost, composition or availability of plastics and resins could adversely affect the business.
• The company may not realize the benefits expected from the Operational Excellence Program.
• Non-compliance with applicable laws or regulations could adversely affect the financial condition and results of operations.
• The company is subject to fraud and abuse and other healthcare laws and regulations.
• The company is exposed to fluctuations in currency exchange rates, which could adversely affect cash flows and results of operations.

Future Outlook

Haemonetics believes that Plasma and Hospital have growth potential, while Blood Center competes in challenging markets that require cost management and rationalization.

Management Comments

• The company challenges itself to think big and make new possibilities a reality, so that its customers can make it matter for patients, every single day.

Industry Context

The medical device markets in which Haemonetics participates are highly competitive and characterized by extensive research and development and rapid technological change. The company faces competition from several large, global companies with product offerings similar to its own.

Comparison to Industry Standards

• In the automated plasma collection market, Haemonetics principally competes with Fresenius Fenwal Aurora and Aurora Xi device product lines and Terumo BCT's Rika device.
• In the whole blood business, Haemonetics' main competitors are Fresenius, MacoPharma and Terumo BCT.
• In femoral access closure for coronary and peripheral procedures, Haemonetics' main competitors include Terumo BCT, Abbott Laboratories and Cardinal Health.
• In hemostasis management, competition includes routine coagulation tests marketed by Werfen, Diagnostica Stago SAS and Sysmex, and viscoelastic testing systems including ROTEM analyzers, the VerifyNow System and HemoSonics Quantra.
• In the intraoperative autotransfusion market, Haemonetics' Cell Saver technology competes principally with products offered by LivaNova PLC, Medtronic and Fresenius.
• In the transfusion management software market, SafeTrace Tx competition primarily consists of stand-alone BBIS including WellSky and some electronic health record software that includes a built-in transfusion management solution including Cerner.

Legal Proceedings

• The company is party to intellectual property litigation.
• The company is subject to product liability claims.
• The company received a subpoena from the U.S. Attorneys Office for the District of Massachusetts requesting documents regarding apheresis and autotransfusion devices and disposables.
• A putative class action complaint was filed against the company in the Circuit Court of Cook County, Illinois, alleging violations of the Illinois Biometric Information Privacy Act.
• A complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. against OpSens, OpSens Medical, Inc., and Haemonetics alleging infringement of a single patent.

Stakeholder Impact

• Shareholders: The company's performance impacts shareholder value and returns.
• Employees: The company's human capital strategy focuses on employee development, engagement, and diversity.
• Customers: The company is dedicated to providing innovative medical technology solutions that improve the quality, effectiveness and efficiency of care.
• Suppliers: The company has a complex global supply chain and is focused on supplier management programs.
• Patients: The company's technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services.

Next Steps

• The company expects to pursue further regulatory clearances for additional enhancements to the overall product offering.
• The company will continue to make investments related to its next generation plasma collection and software systems, the European Medical Device Regulation and In Vitro Diagnostic Regulation and its Hemostasis Management product line.

Key Dates

Keywords

Haemonetics, Plasma, Blood Center, Hospital, Vascular Closure, NexSys PCS, TEG, OpSens, Financial Results, Revenue, Acquisition, FDA Clearance, Operational Excellence, Risk Factors